官方服务：
资源简介：
Sacituzumab Tirumotecan
应用场景：
相关数据集
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
NIAID Data Ecosystem60
Table1_Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study.DOCX
Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid can
NIAID Data Ecosystem40
Available IPD datapackage for study 'A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)'
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of
DataCite Commons2025-05-01 更新30
Data_Sheet_3_Proton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data Base.doc
Background: To investigate the impact of proton radiotherapy (PBT) on overall survival (OS) and evaluate PBT usage trends for patients with gliomas in the National Cancer Data Base (NCDB). Methods: Pa
NIAID Data Ecosystem50
Summarising the therapeutic and adverse effects of antibody-drug conjugates in older women with breast cancer: A review of avaliable clinical trial individual-participant data
Over the last decade there has been substantial advancements in the treatment of breast cancer, including the introduction of the antibody-drug conjugates ado-trastuzumab emtansine, sacituzumab govite
DataCite Commons2025-07-18 更新40
